{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:02:10Z","timestamp":1790755330542,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.oret.2026.04.017","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:26:19Z","timestamp":1777602379000},"page":"984-992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tetracyclines and Risk of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-5157","authenticated-orcid":false,"given":"Itay","family":"Nitzan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6263-9517","authenticated-orcid":false,"given":"Yossi","family":"Eshel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehila","family":"Shlomov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6500-2946","authenticated-orcid":false,"given":"Shoham","family":"Kubovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4614-5673","authenticated-orcid":false,"given":"Nadav","family":"Shemesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Khateb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.04.017_bib1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.survophthal.2024.03.007","article-title":"Clinical therapeutics for proliferative vitreoretinopathy in retinal detachment","volume":"69","author":"Sabatino","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.017_bib2","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41433-025-03846-7","article-title":"Non-surgical interventions for proliferative vitreoretinopathy\u2014a systematic review","volume":"39","author":"Hunter","year":"2025","journal-title":"Eye"},{"key":"10.1016\/j.oret.2026.04.017_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cyto.2011.02.001","article-title":"Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy","volume":"54","author":"Symeonidis","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.oret.2026.04.017_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00417-023-06264-1","article-title":"Proliferative vitreoretinopathy: an update on the current and emerging treatment options","volume":"262","author":"Ferro Desideri","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.017_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000044804","article-title":"Pathogenic mechanisms and treatment advances in proliferative vitreoretinopathy: a review","volume":"104","author":"Dai","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.oret.2026.04.017_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41433-024-03503-5","article-title":"Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review","volume":"39","author":"Toh","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.oret.2026.04.017_bib7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-018-1913-1","article-title":"Tetracycline repurposing in neurodegeneration: focus on Parkinson\u2019s disease","volume":"125","author":"Bortolanza","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.oret.2026.04.017_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.phrs.2011.06.013","article-title":"The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease","volume":"64","author":"Federici","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.oret.2026.04.017_bib9","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","article-title":"Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature","volume":"299","author":"Griffin","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.oret.2026.04.017_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.oret.2026.04.017_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.survophthal.2023.06.007","article-title":"The role of matrix metalloproteinases in infectious corneal ulcers","volume":"68","author":"Garc\u00eda-L\u00f3pez","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.017_bib12","article-title":"Doxycycline ameliorates the severity of experimental proliferative vitreoretinopathy in mice","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oret.2026.04.017_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70198","article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US census","volume":"34","author":"Stein","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.oret.2026.04.017_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jamaophthalmol.2025.2497","article-title":"Mammalian target rapamycin inhibition as a therapeutic target for prevention of proliferative vitreoretinopathy","volume":"143","author":"Alsoudi","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.017_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jamaophthalmol.2025.1851","article-title":"Long-term cannabis use and risk of postoperative proliferative vitreoretinopathy","volume":"143","author":"Alshaikhsalama","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.017_bib17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2018.21554","article-title":"Using the E-value to assess the potential effect of unmeasured confounding in observational studies","volume":"321","author":"Haneuse","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2026.04.017_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/EDE.0000000000000457","article-title":"Sensitivity analysis without assumptions","volume":"27","author":"Ding","year":"2016","journal-title":"Epidemiology"},{"key":"10.1016\/j.oret.2026.04.017_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.oret.2026.04.017_bib21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2337\/diabetes.54.5.1559","article-title":"Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy","volume":"54","author":"Krady","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2026.04.017_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/329418","article-title":"Anti-inflammatory properties of low and high doxycycline doses: an in vitro study","volume":"2015","author":"Di Caprio","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.oret.2026.04.017_bib23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.survophthal.2023.05.007","article-title":"In vitro laboratory models of proliferative vitreoretinopathy","volume":"68","author":"Gao","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.017_bib24","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.3390\/ijms24054509","article-title":"Experimental models to study epithelial-mesenchymal transition in proliferative vitreoretinopathy","volume":"24","author":"Datlibagi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oret.2026.04.017_bib25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1124\/pharmrev.121.000300","article-title":"Nonantimicrobial actions of macrolides: overview and perspectives for future development","volume":"73","author":"Kricker","year":"2021","journal-title":"Pharmacol Rev"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302600179X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302600179X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:40:44Z","timestamp":1790754044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302600179X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S246865302600179X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.04.017","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetracyclines and Risk of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}